Glass packaging specialist SGD Pharma has released its 2025 Sustainability Report, which it says details "significant progress in its sustainable development journey."
In the company’s most recent EcoVadis assessment, it achieved the top-grade Platinum rating with a score of 90/100, placing it among the top one per cent of all companies — for the second time in a row.
This award was earned alongside a parallel CDP Climate A rating, a CDP Supplier Engagement A score and a CDP Water score of B.
These recognitions, the company says, highlight its commitment to embedding sustainability at the core of its strategy and operations, passing the gains to the pharma customer supply chain.
SGD Pharma said that it had achieved a 27% reduction in Scope 1 and Scope 2 greenhouse gas (GHG) emissions in 2025 compared with its 2022 baseline.
This was further supported by major investments in industrial transformation, including the electrification of production processes, the adoption of renewable electricity and the phasing out of heavy fuel oil across its manufacturing sites.
The company added that it is confident in achieving its Science Based Targets initiative (SBTi) commitments, following a 1.5oC trajectory, with ambitious goals to reduce GHG emissions by 42% by 2030.
Olivier Rousseau, CEO, SGD Pharma, said: "Our sustainability strategy is now fully embedded in everything we do and it helps us create value for all our stakeholders: customers, employees, partners, communities and shareholders."
SGD Pharma is not only transforming its operations, but we are also helping shape the future of sustainable healthcare packaging.
Landmark milestones
The company also became the first glass manufacturer in China to achieve ISO 14021 certification for post-consumer recycled content at its Zhanjiang site, which it called a "landmark achievement."
SGD Pharma added that there had been progress across all sites reported, including in:
- improved water efficiency, with reduced withdrawal per tonne produced
- strengthened water stewardship strategy
- biodiversity initiatives, including 16,568 mangroves planted.
SGD Pharma said that it would continue to strengthen sustainability across its global value chain, while recognising that a significant share of its environmental, social and ethical impacts occurs upstream.
In 2025, the Group reinforced its sustainable procurement framework to drive higher standards, improve transparency and support long-term resilience.
All of its critical suppliers have signed a Supplier Code of Conduct, which is aligned with the United Nations Global Compact principles and covers key areas including human rights, labour standards, environmental performance and ethical business practices.
At the same time, 95% of critical suppliers were assessed through an EcoVadis rating or a comprehensive internal sustainability questionnaire evaluating certifications, environmental management, social responsibility and governance practices.
Rousseau continued: "Building a responsible value chain is essential to achieving meaningful, long-term impact."
By working closely with our suppliers and raising expectations across the board, we are creating shared value while accelerating the transition to more sustainable healthcare packaging.
“Our ambition is to continue raising the bar, building a more resilient, responsible company that creates long-term value for patients, customers, partners and society.”
